DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21427/S-032/S-038

SUPPLEMENT APPROVAL

Eli Lilly and Company
Attention: Isabelle Murray, M.Sc.
Manager, Global Regulatory Affairs
Lilly Corporate Center
Indianapolis, IN 46285

Dear Ms. Murray:

Please refer to your Supplemental New Drug Applications (sNDAs) dated May 13, 2009 (S-032) and April 14, 2011 (S-038), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cymbalta (duloxetine hydrochloride) 20 mg, 30 mg, and 60 mg Capsules.

We acknowledge receipt of your amendments to S-032 dated:

(1) November 9, 2009
(2) November 13, 2009
(3) February 11, 2011
(4) April 29, 2011
(5) September 9, 2011
(6) September 16, 2011 (2)
(7) April 30, 2012
(8) May 7, 2012
(9) June 14, 2012
(10) July 18, 2012
(11) August 2, 2012
(12) August 8, 2012
(13) August 20, 2012

We also acknowledge receipt of your amendments to S-038 dated:

(1) September 16, 2011 (2)
(2) February 13, 2011
(3) April 30, 2012
(4) May 7, 2012
(5) June 14, 2012
(6) July 18, 2012
(7) August 2, 2012
(8) August 8, 2012
(9) August 20, 2012

Reference is also made to the approval letter for Supplement 039 dated September 2, 2011 providing for severe skin reactions language to the package insert and medication guide.

The "Prior Approval" supplemental new drug application, S-032, provides for a comprehensive medication guide as requested in an Agency Supplement Request letter dated April 16, 2009. The "Prior Approval" supplemental new drug application, S-038, provides for revisions to Sections 5.7 (Discontinuation of Treatment with Cymbalta) & 6.3 (Common Adverse Reactions).

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Hiren Patel, Regulatory Project Manager, at (301) 796-2087.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS P LAUGHREN
08/24/2012